Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metabolomics | 12 | 2020 | 81 | 3.370 |
Why?
|
| Bile Acids and Salts | 7 | 2020 | 33 | 1.990 |
Why?
|
| Obesity | 5 | 2020 | 1067 | 0.980 |
Why?
|
| Metabolome | 7 | 2019 | 53 | 0.950 |
Why?
|
| Cytochrome P-450 CYP3A | 4 | 2020 | 24 | 0.700 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 4 | 0.660 |
Why?
|
| Ammonia | 1 | 2018 | 17 | 0.660 |
Why?
|
| Hepatic Encephalopathy | 1 | 2018 | 11 | 0.660 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 13 | 0.650 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 111 | 0.640 |
Why?
|
| Cognition Disorders | 1 | 2020 | 233 | 0.640 |
Why?
|
| Hepacivirus | 1 | 2018 | 62 | 0.630 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 52 | 0.630 |
Why?
|
| Mycotoxins | 1 | 2017 | 12 | 0.620 |
Why?
|
| Programming Languages | 1 | 2018 | 28 | 0.620 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 122 | 0.610 |
Why?
|
| Tea | 1 | 2017 | 45 | 0.600 |
Why?
|
| Food Contamination | 1 | 2017 | 55 | 0.600 |
Why?
|
| Liver | 3 | 2019 | 479 | 0.590 |
Why?
|
| Glucose Transporter Type 5 | 1 | 2016 | 1 | 0.580 |
Why?
|
| Mannitol | 1 | 2016 | 11 | 0.580 |
Why?
|
| Cytarabine | 1 | 2016 | 8 | 0.570 |
Why?
|
| Fructose | 1 | 2016 | 22 | 0.570 |
Why?
|
| Blood Glucose | 1 | 2018 | 353 | 0.560 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 30 | 0.560 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 485 | 0.560 |
Why?
|
| Computational Biology | 2 | 2018 | 293 | 0.550 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2015 | 2 | 0.540 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2015 | 4 | 0.540 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 34 | 0.520 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 1502 | 0.490 |
Why?
|
| Humans | 30 | 2020 | 37093 | 0.480 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 61 | 0.430 |
Why?
|
| Middle Aged | 14 | 2020 | 10129 | 0.410 |
Why?
|
| Female | 22 | 2020 | 20969 | 0.410 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 186 | 0.400 |
Why?
|
| Lipids | 1 | 2013 | 235 | 0.390 |
Why?
|
| Prognosis | 5 | 2018 | 739 | 0.390 |
Why?
|
| Mass Spectrometry | 4 | 2018 | 260 | 0.370 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 626 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 807 | 0.360 |
Why?
|
| Principal Component Analysis | 4 | 2018 | 89 | 0.340 |
Why?
|
| Deoxycholic Acid | 2 | 2019 | 10 | 0.340 |
Why?
|
| Adult | 14 | 2020 | 11712 | 0.340 |
Why?
|
| Male | 15 | 2020 | 20025 | 0.330 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 441 | 0.320 |
Why?
|
| Amino Acids | 2 | 2019 | 145 | 0.320 |
Why?
|
| Animals | 11 | 2020 | 15081 | 0.310 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 119 | 0.300 |
Why?
|
| Aged | 10 | 2020 | 6741 | 0.300 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1369 | 0.290 |
Why?
|
| Homeostasis | 2 | 2018 | 188 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 172 | 0.280 |
Why?
|
| Circadian Rhythm | 2 | 2018 | 225 | 0.270 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 2379 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 128 | 0.260 |
Why?
|
| Software | 2 | 2018 | 217 | 0.260 |
Why?
|
| Energy Metabolism | 2 | 2018 | 168 | 0.260 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 2016 | 81 | 0.250 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2016 | 67 | 0.240 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 421 | 0.240 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 583 | 0.230 |
Why?
|
| Mice | 6 | 2020 | 5913 | 0.220 |
Why?
|
| Cohort Studies | 2 | 2018 | 1492 | 0.220 |
Why?
|
| Overweight | 2 | 2015 | 247 | 0.220 |
Why?
|
| ROC Curve | 2 | 2018 | 138 | 0.190 |
Why?
|
| Disease Progression | 2 | 2020 | 601 | 0.190 |
Why?
|
| Case-Control Studies | 4 | 2020 | 1130 | 0.190 |
Why?
|
| Cholates | 1 | 2020 | 1 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2020 | 894 | 0.180 |
Why?
|
| Signal Transduction | 3 | 2019 | 1908 | 0.180 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2020 | 182 | 0.180 |
Why?
|
| Fetal Blood | 1 | 2020 | 50 | 0.180 |
Why?
|
| Microsomes, Liver | 4 | 2020 | 70 | 0.170 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 259 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 15 | 0.170 |
Why?
|
| Lyases | 1 | 2019 | 51 | 0.170 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2018 | 3 | 0.160 |
Why?
|
| Intestines | 1 | 2018 | 64 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 59 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 106 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2018 | 88 | 0.160 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 2231 | 0.160 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 111 | 0.160 |
Why?
|
| Colitis | 1 | 2019 | 65 | 0.160 |
Why?
|
| Stochastic Processes | 1 | 2018 | 10 | 0.160 |
Why?
|
| Oxidation-Reduction | 4 | 2020 | 431 | 0.160 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2018 | 42 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 86 | 0.150 |
Why?
|
| Probability | 1 | 2018 | 78 | 0.150 |
Why?
|
| Limit of Detection | 1 | 2018 | 59 | 0.150 |
Why?
|
| Hyperglycemia | 1 | 2018 | 55 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 145 | 0.150 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 935 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 643 | 0.150 |
Why?
|
| Mothers | 1 | 2020 | 181 | 0.150 |
Why?
|
| Odds Ratio | 2 | 2018 | 534 | 0.150 |
Why?
|
| Algorithms | 2 | 2018 | 465 | 0.150 |
Why?
|
| Models, Biological | 2 | 2018 | 677 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 885 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 190 | 0.150 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 4 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 160 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 186 | 0.140 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 15 | 0.140 |
Why?
|
| Internet | 1 | 2018 | 211 | 0.140 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2016 | 18 | 0.140 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 52 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2018 | 180 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2018 | 291 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1371 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 40 | 0.140 |
Why?
|
| Fanconi Anemia Complementation Group L Protein | 1 | 2016 | 2 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2016 | 177 | 0.140 |
Why?
|
| DNA Methylation | 2 | 2018 | 325 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 623 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 173 | 0.140 |
Why?
|
| Computer Simulation | 1 | 2018 | 362 | 0.130 |
Why?
|
| Hydroxylation | 3 | 2020 | 15 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2020 | 854 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 194 | 0.130 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 103 | 0.130 |
Why?
|
| China | 1 | 2015 | 196 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2015 | 195 | 0.130 |
Why?
|
| Cell Line | 1 | 2018 | 1354 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2018 | 484 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 400 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2016 | 513 | 0.120 |
Why?
|
| Mitochondria | 1 | 2017 | 487 | 0.110 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 23 | 0.110 |
Why?
|
| Sphingomyelins | 1 | 2013 | 11 | 0.110 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 43 | 0.110 |
Why?
|
| Lysophosphatidylcholines | 1 | 2013 | 22 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 905 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 312 | 0.110 |
Why?
|
| Phenotype | 1 | 2015 | 689 | 0.110 |
Why?
|
| Arsenic | 1 | 2015 | 144 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2016 | 384 | 0.110 |
Why?
|
| Mutation | 1 | 2017 | 1095 | 0.110 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 289 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 275 | 0.100 |
Why?
|
| Diet | 1 | 2018 | 801 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 664 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 974 | 0.100 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2026 | 0.090 |
Why?
|
| Neoplasms | 1 | 2018 | 1103 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2721 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2019 | 933 | 0.070 |
Why?
|
| Young Adult | 4 | 2019 | 4268 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 441 | 0.070 |
Why?
|
| Pregnancy | 2 | 2020 | 1549 | 0.060 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2020 | 29 | 0.050 |
Why?
|
| Germ-Free Life | 1 | 2020 | 3 | 0.050 |
Why?
|
| Urine | 1 | 2020 | 13 | 0.050 |
Why?
|
| Connecticut | 1 | 2020 | 14 | 0.050 |
Why?
|
| New Jersey | 1 | 2020 | 15 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2020 | 55 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 112 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 2020 | 167 | 0.040 |
Why?
|
| Dogs | 1 | 2020 | 149 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2020 | 212 | 0.040 |
Why?
|
| Species Specificity | 1 | 2020 | 245 | 0.040 |
Why?
|
| Feces | 1 | 2020 | 111 | 0.040 |
Why?
|
| Birth Weight | 1 | 2020 | 90 | 0.040 |
Why?
|
| Interleukin-16 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 3562 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 14 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 220 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 60 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 139 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 212 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2019 | 65 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2020 | 125 | 0.040 |
Why?
|
| Meat | 1 | 2018 | 43 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2019 | 78 | 0.040 |
Why?
|
| CpG Islands | 1 | 2018 | 97 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 308 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2018 | 325 | 0.040 |
Why?
|
| Selenium | 1 | 2019 | 148 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 708 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 562 | 0.040 |
Why?
|
| Heterozygote | 1 | 2017 | 93 | 0.040 |
Why?
|
| Vegetables | 1 | 2018 | 147 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 156 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 922 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 1033 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 435 | 0.040 |
Why?
|
| Germ Cells | 1 | 2017 | 73 | 0.040 |
Why?
|
| Automation | 1 | 2016 | 22 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 893 | 0.040 |
Why?
|
| Workflow | 1 | 2016 | 20 | 0.030 |
Why?
|
| Methionine | 1 | 2016 | 30 | 0.030 |
Why?
|
| Threonine | 1 | 2016 | 25 | 0.030 |
Why?
|
| Phenylalanine | 1 | 2016 | 25 | 0.030 |
Why?
|
| Transgenes | 1 | 2016 | 59 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 174 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2019 | 339 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 17 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 928 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 85 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 130 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 75 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2015 | 63 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 113 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 93 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 142 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 190 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 358 | 0.030 |
Why?
|
| Adolescent | 2 | 2016 | 5363 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1609 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 240 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 515 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 674 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1015 | 0.030 |
Why?
|
| Rats | 1 | 2020 | 3483 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2015 | 1378 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1198 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1398 | 0.020 |
Why?
|